Skip to content
Open access

Development and external validation of a clinical prediction model to estimate unfavorable graft outcome in patients with severe kidney transplant rejection eligible for treatment with alemtuzumab.

Oct 2026 · Immunobiology · Vol 231 6, pp. 153261 · 0 citations · 35 references
Medicine

Abstract

INTRODUCTION Alemtuzumab is an effective therapy for severe kidney transplant rejection. Yet, not all patients benefit from this treatment, while they are at risk for its toxic effects. A prediction model could help to identify these patients and potentially guide treatment decisions.

Methods

We developed a prediction model using logistic regression and four prespecified, clinical predictor variables on a clinical dataset of two hundred patients who were treated for glucocorticoid-resistant and/or severe kidney transplant rejection with alemtuzumab. The outcome was a composite of graft loss or having a marginal graft function over the entire six months post-treatment. The model was internally validated using bootstrapping and a pilot external validation was performed with an independent validation cohort (n = 96). To make optimal use of the available data, the model was refitted to the combined datasets. Its potential for clinical utility was subsequently assessed with a decision curve analysis.

Results

The model included the predictors rejection subtype, timing, donor type, and dialysis dependence. It showed an optimism-corrected c-statistic and calibration slope of 0.75 and 0.81. The pilot external validation demonstrated a c-statistic of 0.71 and calibration slope of 0.86. There was a potential benefit of model-informed treatment decisions over a 'treat-all' strategy.

Conclusion

The model showed moderate discrimination and reasonable calibration for estimating the risk of an unfavorable graft outcome after alemtuzumab treatment and warrants further external validation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.